Drug Discovery Alert (TechVision) · Technology Convergence Sanofi will use VECT-HORUS’...
Transcript of Drug Discovery Alert (TechVision) · Technology Convergence Sanofi will use VECT-HORUS’...
Drug Discovery Alert (TechVision)
Novel Drug Delivery Systems in the Spotlight
D951-TV
April 08, 2016
2 D951-TV
Section Slide Number
Trend Overview 3
Novel Drug Delivery Systems (NDDS) in the Spotlight 4
Technology Profiles in Drug Delivery Systems 5
Pioneering Digital Health and Smart Drug Delivery Systems
BIOCORP 6
Natural Monodisperse Phytoglycogen Nanomaterials for Advanced Drug Delivery
Glysantis, Inc. 7
Facilitating the Transport of Drugs and Imaging Agents via Molecular Vectors
VECT-HORUS 8
Microneedle Pill with Hollow Needles
Massachusetts Institute of Technology (MIT) – Massachusetts General Hospital (MGH) 9
New Liposomal Vesicles to Help Treat Coronary Artery Disease
The University of Basel 10
Biocompatible Targeted Cancer Therapy
Keystone Nano, Inc. 11
Nanoparticle Based Technology to Improve Drug Bioavailability
Camurus AB 12
Appendix 13
Patent Analysis 14
Industry Interactions 17
Contents
3 D951-TV
Trend Overview
4
The Novel Drug Delivery Systems (NDDS) Landscape
Why NDDS became a key concept in pharma development
Worldwide societal trends
Demographic and healthcare policy changes have
increased the complexity in the pharmaceutical and medical
device industries over the past five years. The aging
population, growing middle class, and rising disease burden
with chronic diseases, such as diabetes and cancer and
monitoring of autoimmune disorders therapeutics, and
metabolic diseases, among many others, represent just a
few issues that need to be addressed urgently.
xx
Value-based care concept
Moving toward a value-based care concept
of medicine, which strives for cost- and time-
efficient tools and digital instruments,
healthcare providers are re-shaping
healthcare delivery care models. The overall
structure of the industry, including the long
expedition from innovation to
commercialization, turns market access into
a challenging mission. However, with the
advent of digital technologies across a broad
spectrum of industries, users are becoming
confident in the use of digital equipment and
connected health notions. This can drive
adoption of novel technologies.
Self-administration trend
Devices need to be designed to prevent or
reduce user errors and patient data need
to be protected taking advantage of
connected health solutions and mobile
health applications. Therefore, these
challenges can be turned into huge
opportunities thanks to the greater
integration between informatics
applications and drug delivery and
administration devices, especially meeting
the need for medication adherence,
controlled release, and self-administration,
among others.
Shift toward biologics
In personalized medicine, the rules of the game are
changing in pharmaceutical development and
manufacturing activities, ranging from small molecules to
biologic drug products. The formulation of these complex
macromolecules is significantly more challenging than
their small-molecule counterparts.
Drug Delivery Systems A Brief Overview
5 D951-TV
Technology Profiles
6
Technology
Readiness Level
Biocorp is
open to
collaborations
with leading
medtech and
pharmatech
companies,
hospitals, and
institutes.
1 2 3
4 5 6
7 8 9
Wide-scale Adoption
The critical unmet need is the lack of contact and
interfacing between the patient and clinicians during
homecare treatment. Companies need to develop
new technologies in sync with equipment used
commonly, such as smartphones and tablets.
Biocorp’s ultimate goal is to increase the level of
treatment adherence of the patients and their overall
comfort.
Market Opportunity
Biocorp has invested in drug delivery
devices, more specifically, smart drug
delivery devices, convinced that the
healthcare system is changing very rapidly
and pharmaceutical companies need to
provide new solutions to their patients for
long term, chronic/debilitating diseases. The
company promptly understood the significant
market opportunity in this regard.
Vertically integrated connected health technology platform
to enhance drug delivery systems. BIOCORP is focused on
the development of innovative medical devices and drug
delivery systems. The platforms are based on three main
units: medical devices manufacturing, research and
development, and informatics technology.
Technology Profile
Aiming to achieve an in-depth understanding of customers’ real
needs, Biocorp works very closely with pharma companies
developing devices up to the functional prototype phase.
Customization programs and collaborative projects with large
companies are strategies followed by Biocorp to bring innovative
solutions to the industry.
Innovation Attributes
Biocorp is focused on therapeutic areas with major unmet
needs, thus contributing more efficient medical devices
from a holistic perspective. Biocorp develops no less than
two products per year on average, which constitutes a
significant milestone in the medical device sector. The
company’s vision is to connect existing medical devices
through novel sensors and data acquisition technologies to
gather precious information.
Competing Aspects
Biocorp’s strategy is to be the first to innovate, not follow. The
very first step for initiating a new project is to understand the
needs of patients and clinicians and translate these needs into
technical solutions. Biocorp is open to any collaborations with
medtech companies and healthcare centers and facilities to
deliver the best solutions for patients
Market Entry Strategies
D951-TV
Technology Convergence
Biocorp hopes that all the devices will be
connected with smartphones, tablets, and
other IT tools to keep track of treatment of
patients in real time and provide
information. In the oncology and
immunology therapeutic areas, there is a
need to shift from inpatient to outpatient
care protocols.
Impact & Opportunities
Pioneering Digital Health and Smart Drug Delivery Systems BIOCORP
7
Technology
Readiness Level
NanoGlys is
available for early
stage licensing
and partnering
with major
participants in the
fields of
antibiotics,
immuno-
modulators and
cancer.
1 2 3
4 5 6
7 8 9
Wide-scale Adoption
Glysantis leverages the vast potential of nanotherapy in
medicine by using safe, water-soluble, benign, mono-
disperse nanoparticles as the foundation for a wide
variety of new developments. Glysantis’ vision is to make
this inherently safe technology platform widely available
for drug development to improve the standard of care for
patients in wide areas of medicine, especially for patients
with severe or chronic diseases. The total market
potential in areas such as cancer treatment, antibiotics,
immunomodulators and imaging is above $100 billion.
Market Opportunity
NanoGlys-based antimicrobial therapeutic agents help to
fight infectious disease. In vitro immunomodulation
studies with Glysantis lead compounds showed
performance far above benchmark effects. In vitro
biodistribution studies using markers demonstrate
passive targeting of cancer tissue and also high affinity
to other tissues/organs.
NanoGlys particles created by nature in certain varieties of sweet
corn. Glysantis has found a way to preserve the natural particle
structure during the extraction and purification of this highly
monodisperse nano-material. The unique properties of this nano-
material make it an ideal platform for drug development, that is, it is
highly water soluble and non-toxic, biodegradable, and versatile. It
can be easily modified by standard methods in carbohydrate
chemistry (including the chemical attachment of drugs, biomarkers,
etc.) and is a “stealth carrier” as it is practically invisible to the
immune system.
Technology Profile
Phytoglycogen is hydrophilic, fully biodegradable and becomes a part of
the regular glucose metabolism when administered, which avoids
accumulation of the nano-carrier during treatment or residual nano-
material after therapy. In contrast to engineered nano-materials,
nanoglycogen and its metabolites do not exhibit safety or toxicity
problems. NanoGlys is just the right size for a highly effective drug
delivery system or application as a nano-probe. It has other advantages
such as a more favorable rate of biodegradation, as well as, better
selectivity and sensitivity. The material is inherently highly
monodisperse--an important feature in many biomedical applications.
Innovation Attributes
Selective targeting and accumulation is a prime feature of drug
delivery carriers, as well as the release of the drug at its destination.
With liposomes, one of the FDA-approved nano-carriers, the drug
leaks from the nanoparticle in a time controlled manner. This
approach is limited to a small range of drugs and is not feasible for
biologics. NanoGlys particles use different pathways. Conjugates
have been shown to retain activity of the drug; the drug can be
anchored to NanoGlys with tethers that respond to external stimuli
or biodegradation of nanoglycogen, releasing the drug.
Competing Aspects
Glysantis’ main interest is preclinical development of the technology
platform. Glysantis’ business model is based on early stage licensing and
partnering with potential licensees. The company is reaching out to
other international research groups that have an interest in nano-sized
monodisperse carbohydrates. NanoGlys can be used for a wide range of
clinical indications. The main focus is on areas where the intrinsic
properties of native and modified nanoglycogen can be leveraged to
achieve unique effects, such as antibiotics, immunomodulation, and drug
delivery.
Market Entry Strategies
D951-TV
Technology Convergence
Glysantis believes the promise of
nanotechnology in medicine can yet be
fulfilled. Research on synthetic
nanomaterials has demonstrated the
potential for exciting therapeutic effects,
yet it has been limited by many inherent
problems with most nanomaterials. This
material provides what is needed to fulfil
this promise: a safe, water-soluble, and
modifiable nano-carrier.
Impact and Opportunities
Natural Monodisperse Phytoglycogen Nanomaterials for Advanced Drug Delivery
Glysantis, Inc.
8
Technology
Readiness Level
VECT-HORUS
plans to become
a major player in
the field of drug
and imaging
agent delivery,
especially in the
CNS. within the
next 5 years
1 2 3
4 5 6
7 8 9
Wide-scale Adoption
VECT-HORUS is also building a pipeline of
proprietary drug candidates for internal development
to reach preclinical or early clinical trials,
subsequently out-licensed to pharma/biotech
companies. VECT-HORUS’ lead compound, VH-
N439, a neuropeptide with global hypothermic
potential, is in regulatory preclinical studies. VH-N439
will be a first-in-class pharmacological agent inducing
therapeutic hypothermia and will be positioned as a
neuroprotective agent for sudden cardiac arrest
(SCA), neonatal ischemia, traumatic brain injury, and
potentially for stroke.
Market Opportunity
The CNS market is one of the largest and fastest
growing markets in the pharmaceutical industry. There is
a strong demand from the pharmaceutical industry for
innovative delivery strategies that could optimize drug
delivery across the BBB, and the potential market for
these technologies is growing rapidly. The market for
BBB technologies is expected to grow to $471.5 million
by 2019. Within this market, the technologies that use
RMT to carry molecules to the brain will represent most
of the growth and should generate sales of $456 million
by 2019. VECT-HORUS has set up various collaborative
programs to generate future revenues.
VECTrans® Technology Platform. This is focused on the
development of molecular vectors that facilitate the transport of drugs
and imaging/diagnostic agents to the brain. VECT-HORUS is focused
on drug delivery technologies to the brain and other tissues, including
tumors, and the development of innovative vectorized drugs and
imaging agents. The brain vascular system prevents the passage of
more than 98% of the drugs developed to date and is thus called the
blood-brain barrier (BBB).
Technology Profile
By combining pharmaceutical agents to its peptide-vectors designed to
target specific receptors, VECT-HORUS promotes delivery of these
agents to target cells or organs and allows them to cross natural
barriers such as the BBB, which significantly impedes brain delivery.
The transport of molecules by receptors (receptor mediated transport
or RMT) is now considered the most effective and safest way to
bypass the BBB. The highly specific and stable vectors identified and
validated by VECT-HORUS are protected by several families of
patents and patent applications.
Innovation Attributes
The BBB excludes from the brain ~100% of large molecules (for
example, antibodies, proteins, peptides) and more than 98% of all
small-molecule drugs, thus representing a real technological barrier to
brain delivery of imaging agents and drugs developed to treat serious
brain diseases (Parkinson’s, multiple sclerosis, Alzheimer's, stroke,
and brain tumors). Therefore, methods that can enhance drug delivery
to the brain are of great interest.
Competing Aspects
VECT-HORUS’ business model is based on external (R&D contracts
with industrial partners) and internal (in-house pipeline development)
innovation strategies. VECT-HORUS’ mission is to make its highly
innovative VECTrans technological platform available to pharma and
biotech partners by transporting its drugs to the brain and other
organs. VECT-HORUS has granted non-exclusive licenses for its
vectors to industrial partners.
Market Entry Strategies
D951-TV
Technology Convergence
Sanofi will use VECT-HORUS’ proprietary
technology to transport therapeutic antibodies
into the brain for the treatment of a
neurodegenerative disease. Another
collaboration in the field of medical imaging is
focused on innovative nuclear/molecular
conjugates targeting the brain or other
organs/cancer tissues outside of the nervous
system. Recently, a collaboration agreement
was signed with Servier to transport a
therapeutic peptide into the brain for an
undisclosed indication.
Impact & Opportunities
Facilitating the Transport of Drugs and Imaging Agents via Molecular Vectors VECT-HORUS
"The agreements signed with our pharma partners reflects the growing interest in our drug delivery platform and validate the potential of our technology to facilitate the addressing of
diagnostic and therapeutic molecules to different organs and particularly to the brain”, says Dr Jamal TEMSAMANI, Director of Drug Development & Corporate of VECT-HORUS.
9
Technology Readiness
Level
Most patients prefer to take a drug orally
instead of getting an injection. However,
drugs made from large proteins cannot be
given as a pill as they would break up in
the stomach before they can be
absorbed. This capsule may potentially
serve as a novel technology platform for
the delivery of a broad spectrum of
therapeutics. This fact is specially
important in payload direction into the
lining of the gastrointestinal tract and
prevention of drug degradation.
Wide-scale Adoption
Many attempts to design
microparticles and nanoparticles to
deliver biologics have failed,
especially taking into account the
expensive cost and the need for re-
engineering the prototype for each
drug.
Market Opportunity
Coated with short needles, the product has
demonstrated safety. There are no pain
receptors in the gastrointestinal tract, so
patients would not feel any pain from the
drug injection. The pill would take at least a
week to move through the entire digestive
tract. This achievement is the result of tech
convergence.
Technology Convergence
The opportunities for this development are not
limited to diabetes care via insulin delivery.
Biopharmaceuticals such as antibodies for
immuno-oncology, including vaccines,
recombinant DNA and RNA can be successfully
delivered through this technology.
Market Entry Strategies
Novel drug capsule coated with tiny
needles that can inject drugs directly
into the lining of the stomach after the
capsule is swallowed. The research
was funded by the National Institutes of
Health.
Technology Profile
This insulin delivery system has
demonstrated more efficiency in animals
than subcutaneous injections and safety,
exhibiting no harmful side effects as the
capsule passed through the digestive
system.
Competing Aspects
The prototype consists of an acrylic capsule of 2
x 1 centimeters in length and diameter,
respectively, comprising a reservoir for the
drug. The capsule is coated with hollow,
stainless steel needles approximately 5
millimeters long.
Innovation Attributes
2
1
3
4
5 6
7
8
9
D951-TV
Microneedle Pill with Hollow Needles Massachusetts Institute of Technology (MIT) – Massachusetts General Hospital (MGH)
10
Technology Readiness
Level
As these liposomes resulted in no or
negligible reaction in blood serum of pigs,
it is expected that the researchers will be
able to achieve similar results in human
bodies too. However, there is a long way
to go before this research initiative will be
clinically evaluated in human adults.
Wide-scale adoption is only expected
upon completion of exhaustive pre-clinical
tests and human clinical trials.
Wide-scale Adoption
According to World health Organization
(WHO), coronary artery disease results in
an estimated 30% of the deaths worldwide
and there is a huge demand for medication
that can efficiently cover pre-hospital
medical aid, that is, before the patient is
transported to the hospital for surgical
treatment.
Market Opportunity
Liposomes in drug delivery have found
widespread acceptance in the last decade
as they are capable of targeted delivery and
embedding the drug molecules inside their
water-filled cavity allows for efficient
transport of the drug. The convergence of
nanotechnology, biology, and medicine is
important and can be used to treat a
number of other coronary heart ailments.
Technology Convergence
The opportunities of this development are not
limited to treatment of coronary artery disease
but can be extended to a number of medical
applications where immune response is
unfavorable, especially in gene therapy and
organ transplants.
Market Entry Strategies
Liposomes are commonly used as drug
delivery vehicles to transport drugs to
various organs in the human body.
However, since they are identified as
foreign substances by the immune system
in the body, the activation of immune
response leads to pseudo-allergy that can
lead to harmful anaphylactic shocks.
Technology Profile
The research team at the University of
Basel has developed artificial liposomal
vesicles in a lenticular form for drug
delivery to constricted coronary arteries.
However, the major competing aspect is
the fact that these artificial vesicles do not
elicit any immune response in the human
body and are completely ignored by the
immune system.
Competing Aspects
Artificial phospholipid vesicles (Pad-PC-Pad vesicles)
were injected in three Yorkshire pigs and their heart
rate, electrocardiogram (ECG) and blood pressure
was monitored. High doses of these vesicles resulted
in negligible reactions and no toxic changes in
kidneys, lungs, heart, and liver were noticed in tissue
biopsies.
Innovation Attributes
2
1
3
4
5 6
7
8
9
D951-TV
New Liposomal Vesicles to Help Treat Coronary Artery Disease The University of Basel
11
Technology Readiness
Level
The company has so far tested the
NanoJackets with a host of
pharmaceutical therapies in cells and
human cancer models (in vitro) and has
received satisfactory results. Further
clinical testing is required before the
company can file for regulatory approvals
in the respective regions. Wide-scale
adoption of the technology is expected by
2020.
Wide-scale Adoption
Targeted cancer therapies hold a major
share in the total cancer therapy market.
Many pharmaceutical and biotechnology
companies are drawn by the continuous
success of targeted cancer therapies. The
technology developed by Keystone Nano
has huge potential in this market.
Market Opportunity
The NanoJacket technology being
developed by Keystone Nano can be used
to transform liver, pancreatic and breast
cancer treatment with fewer side-effects.
Through size and surface change, a wide
range of targeting materials can be
attached to the surface and used for other
applications.
Technology Convergence
Keystone Nano is currently commercializing
NanoJacket products and Ceramide
NanoLiposome for a number of medical
applications. With 14 issued patents and 8
pending patents, the product pipeline of the
company is expected to cater to cancer therapy
needs.
Market Entry Strategies
Targeted cancer therapies have found
widespread coverage in the last decade
owing to its capability to treat various
tumors in the human body. The
conventional methods of tumor therapy
include radio and chemotherapy and they
are extremely dangerous for the
surrounding healthy tissues.
Technology Profile
The company has developed the
NanoJacket technology that is a novel
biocompatible, composite nanoparticle
technology with the ability to improve the
effectiveness of cancer therapies. The
NanoJacket technology has the ability to
load both hydrophilic and hydrophobic
compounds as active ingredients.
Competing Aspects
To improve biocompatibility and acceptance with the
immune system, the NanoJackets are made up of
calcium, phosphate, and silicates that occur naturally
in the body. With a size of 5-50 nanometers,
NanoJacket particles can circulate well in blood and
enter tumor cells to destroy them. The active
pharmaceutical ingredients are stored inside
NanoJackets that prevent degradation of the drug
during circulation.
Innovation Attributes
2
1
3
4
5 6
7
8
9
D951-TV
Biocompatible Targeted Cancer Therapy Keystone Nano, Inc.
12
Technology Readiness
Level
With enhanced delivery over topical
administration routes, the FluidCrystal
nanoparticle technology holds
promise and the company is currently
developing a range of products based
on it. As the products are still in the
clinical trial stages and require
regulatory review, wide-scale
adoption is expected toward the end
of 2019.
Wide-scale Adoption
The global drug delivery market is a multi-
billion dollar market that has witnessed a
huge change in delivery formulations in the
last decade. The novel nanoparticle-based
technology from the company has huge
potential to disrupt the way drugs are
delivered inside the human body.
Market Opportunity
Camurus’ technology addresses a number
of unmet medical needs. The company is
developing products to treat a range of
therapeutic areas such as cancer, chronic
pain, opioid dependence, endocrinology
and other disease areas. All these products
are in different development stages
currently.
Technology Convergence
Camurus has partnered with a number of firms in
the biotech space to promote clinical trials of its
existing products. One of the key partnerships
has been with Braeburn Pharmaceuticals, a
company delivering precision medicine, to initiate
Phase III trial of its opioid dependence treatment
drug. Ultimately, Camurus is expected to
leverage this partnership to commercialize its
product once it receives regulatory approvals.
Market Entry Strategies
Amphiphilic drugs and lipophilic drugs often face
bioavailability issues once they are administered
to the human body as they often lose their
strength after passing through the Gastro-
intestinal (GI) tract in the human body. As a
result, less than half the quantity of the drug is
made available at the desired site in the body.
The FluidCrystal nanoparticles technology has
been developed to address these bioavailability
limitations.
Technology Profile
The FluidCrystal technology has been
developed by the company to increase
bioavailability of lipophilic drugs that have low
aqueous solubility and also for biodegradation-
sensitive drugs, especially proteins and
peptides, that are difficult to transport across cell
membranes otherwise.
Competing Aspects
FluidCrystal nanoparticles are water-based
substances and consist of a stable emulsion of
nanoparticles that have a liquid crystalline
structure. Products based on this technology
enhance systemic circulation of the drugs and are
preformed to stable dispersions that can be
applied to the skin or mucous membranes in the
spray form or injected intravenously or
subcutaneously or through an intramuscular or
intracavital injection.
Innovation Attributes
2
1
3
4
5 6
7
8
9
D951-TV
Nanoparticle-Based Technology to Improve Drug Bioavailability Camurus AB
13 D951-TV
Appendix
14
Title Publication
Date/Publication
Number
Assignee Abstract
Drug delivery device with
means for disabling
activation of expelling
mechanism
31.03.2016/
US20160089500
Novo Nordisk
A/S
A drug delivery device has a cartridge holder adapted to receive and hold a
cartridge, the cartridge holder having a receiving and a holding state. The device
further comprises a drive assembly with a piston rod and a drive spring, setting
means allowing a user to set a dose amount to be expelled and strain the drive
spring correspondingly, and user actuated release means for releasing the drive
spring, wherein the drive assembly spring cannot be released to move the piston rod
unless the cartridge holder is in the holding state.
Drug delivery device
including electrolytic
pump
31.03.2016/
US20160089490
King Abdullah
University of
Science and
Technology
Ian G. FouldsSystems and methods are provided for a drug delivery device and use
of the device for drug delivery. In various aspects, the drug delivery device combines
a “solid drug in reservoir” (SDR) system with an electrolytic pump. In various
aspects an improved electrolytic pump is provided including, in particular, an
improved electrolytic pump for use with a drug delivery device, for example an
implantable drug delivery device. A catalytic reformer can be incorporated in a
periodically pulsed electrolytic pump to provide stable pumping performance and
reduced actuation cycle.
Patents related to Picture Credit: Frost & Sullivan; WIPO Database
Drug delivery primarily refers to transporting a pharmaceutical compound, usually a drug, in to provide the therapeutic effect required by
the body. A number of medical devices or drug delivery devices have been developed for this purpose which deliver the formulation at
the required site. Drug delivery systems are extremely crucial to deliver drugs to the human body especially for people who require drugs
at regular intervals, such as diabetics requiring doses of insulin. Targeted delivery is one of the most recent trends associated with drug
delivery technologies. In targeted delivery, the drug or the pharmaceutical formulation is only active at the target site and does not affect
the surrounding tissues in the human body. One of the most researched areas of targeted delivery includes pharmaceutical compositions
targeted at cancerous tissues in the human body. Targeted delivery ensures that none of the surrounding healthy tissue is affected as a
result. Drug carriers form an essential aspect of drug delivery systems, as they are expected to enhance the bioavailability of the drug in
the human body as well as provide stability and solubility to the drug to help initiate its mode of action.
D950-TV
Patents Related to Novel Drug Delivery Systems
15
Title Publication
Date/Publication
Number
Assignee Abstract
Nanoporous micro-
spherical polyimide
aerogels and method for
preparing same
31.03.2016/
WO/2016/047821
Industry-Academic
Cooperation
Foundation,
Yonsei University
The present invention relates to nanoporous micro-spherical polyimide
aerogels and a method for preparing the same. The use of the method for
preparing polyimide aerogels, according to an embodiment of the present
invention, enables the preparation of the polyimide aerogels through a low-
temperature process, and thus can save energy and time when compared
with existing preparing methods, can reduce production costs, and can
prepare spherical polyimide aerogels, which are micro-sized uniform
particles, having excellent chemical stability, thermal insulation
characteristics, and absorption-desorption characteristics while having nano-
sized pores. The spherical polyimide aerogels can be applied to various
fields, such as an insulator, a drug delivery medium, and a catalyst supporter,
due to excellent physical properties thereof.
Vibration sensor based
drug delivery monitor
31.03.2016/
WO/2016/049066
Oscillari LLC A monitoring system comprising a monitor that utilizes a vibration sensor to
monitor the occurrence and properties of events. The monitor does not
require disassembly of the device to be monitored, or interfere with operation
of the device monitored and maybe affixed to the exterior of a device to be
monitored or a component thereof, or be integrated into the design of the
device. The device to be monitored may be a drug delivery device such as an
inhaler or autoinjector. The monitoring system includes a display device such
as a smartphone or tablet computer for analyzing data related to the device to
be monitored usage and displaying information to a user, patient and/or
caregiver before, during, and after a usage event such as the inhalation flow
rate through an inhaler, and the dose delivered by an injector.
Picture Credit: Frost & Sullivan; WIPO Database
D950-TV
Patents Related to Novel Drug Delivery Systems
16
Title Publication
Date/Publication
Number
Assignee Abstract
Devices and methods for
delivering a beneficial
agent to a user
31.03.2016/
WO/2016/049224
Abbvie Inc. Drug delivery reservoir for delivery of a beneficial agent to a user includes a
drug delivery reservoir housing (10) having a fluid reservoir (12) defined
therein. The drug delivery reservoir housing (10) has a drug delivery reservoir
base region (83). The drug delivery reservoir includes a dip tube (13) extending
inside the fluid reservoir. The dip tube (13) includes a tubular wall defining a
flow lumen. The tubular wall has at least one aperture (14) defined therein and
spaced proximally from a distal end of the tubular wall in fluid communication
with the fluid reservoir. The drug delivery reservoir includes an adaptor (15)
disposed external to the drug delivery reservoir housing (10) and coupled to a
proximal end of the dip tube.
Metal embedded
hydrophilic polymer for
drug delivery applications
31.03.2016/
WO/2016/046847
Council of
Scientific &
Industrial
Research
The present invention discloses a porous polymer for drug delivery application
comprising poly(acrylic acid-co-trimethylolpropane triacrylate) supported gold
or poly(methacrylic acid- co-pentaerythritol triacrylate) supported silver/copper
for controlled and selective in vitro drug delivery.
Picture Credit: Frost & Sullivan; WIPO Database
D950-TV
Patents Related to Novel Drug Delivery Systems
17
Industry Interactions
Chief Executive Officer,
Glysantis Inc.,
Canada
Phone: +1-905-339-9907
E-mail: [email protected]
Phil Whiting
Postdoctoral Fellow and Entrepreneur,
Massachusetts Institute of Technology,
77 Massachusetts Avenue Cambridge, MA 02139-
4307.
Phone: +617-253-3107
Fax: +617-258-8827
E-mail: [email protected]
URL: https://dbgroup.mit.edu/carl-schoellhammer
President,
Glysantis Inc.,
361 Southgate Drive - Unit C, Guelph,
Ontario N1G 3M5, Canada.
Phone: +1-919-923-2159.
E-mail: [email protected]
URL: http://www.glysantis.com/
Thomas Engelhardt
Head of Business Development and
Commercial Operations, BIOCORP.
Parc Technologique Lavaur-la-
Béchade, 63500 Issoire, France.
Phone : +33-6-08-02-14-51
Fax : +33-4-73-55-01-86
E-mail: [email protected]
URL: http://www.biocorp.fr/
Eric Dessertenne
PhD, Director of Drug Development and
Corporate, VECT-HORUS,
Faculté de Médecine, Secteur Nord, CS80011,
51, Bd Pierre Dramard, 13344 - Marseille
Cedex 15, France.
Phone: +33-4-91-69-87-81
E-mail: [email protected]
URL: http://www.vect-horus.com/
Jamal Temsamani, PhD
Carl Schoellhammer
D951-TV
18
Industry Interactions
President & Chief Executive Officer,
Camurus AB,
Ideon Science Park,
SE-223 70 Lund, Sweden
Phone: +46-46-286-46-92
E-mail: [email protected]
URL: http://www.camurus.com/home/
Fredrik Tiberg
Chief Executive Officer,
Keystone Nano, Inc.,
1981 Pine Hall Rd,
State College PA 16801.
Phone: +1-814-237-4657
E-mail: [email protected]
URL: http://www.keystonenano.com/
Jeff Davidson
D951-TV
Professor,
Biomaterials Science Center,
University of Basel,
Gewerbestrasse 14,
4123 Allschwil, Switzerland
Phone: +41-61-265-9660
E-mail: [email protected]
URL: https://bmc.unibas.ch/institute/bert_mueller.phtml
Bert Müller